Please register to participate in our discussions with 2 million other members - it's free and quick! Some forums can only be seen by registered members. After you create your account, you'll be able to customize options and access all our 15,000 new posts/day with fewer ads.
While based in Tarrytown, it does have a big facility in the Rensselaer/East Greenbush area(east of Albany/south of Troy), Regeneron reports ‘successful’ year with $16 billion revenue in 2021: https://www.timesunion.com/business/...ness-spotlight
From the article: "Regeneron had a productive year in 2021 despite pandemic challenges.
The biotech firm earned about $16 billion in revenue, generating net income slightly over $8 billion.
In 2020, Regeneron reported $8 billion in overall revenue for a profit of about $3.5 billion, indicating the company almost doubled its earnings a year later. The net income per diluted share was valued at $71.97 in 2021 compared to $30.52 the year before.
In a letter to shareholders, Regeneron executives said the company delivered a “notably successful and productive year.”
“Our relentless quest to innovate has improved millions of lives while delivering strong top and bottom-line growth for our shareholders,” they wrote.
According to a filing with the Securities and Exchange Commission, Regeneron generated a 32 percent total shareholder return in 2021.
The year’s growth was led by the company’s core medicines, Eylea, Dupixent and Libtayo.
Eylea’s global sales increased by 19 percent, Dupixent sales rose 53 percent and Libtayo sales rose 32 percent. Its COVID-19 antibody cocktail, REGEN-COV, led the jump in revenues contributing $6.19 billion of income."
Please register to post and access all features of our very popular forum. It is free and quick. Over $68,000 in prizes has already been given out to active posters on our forum. Additional giveaways are planned.
Detailed information about all U.S. cities, counties, and zip codes on our site: City-data.com.